厄洛替尼在晚期非小细胞肺癌中的临床应用效果

Clinical application effect of Erlotinib in the treatment of advanced non-small cell lung cancer

目的探讨厄洛替尼治疗晚期非小细胞肺癌的临床效果。方法选取2017年1月~2019年6月中一东北国际医院收治的176例晚期非小细胞肺癌患者作为研究对象,按照随机数字表法分为对照组(88例)与实验组(88例)。对照组采用多西他赛进行治疗,实验组则采用厄洛替尼治疗。比较两组患者的随访1年生存情况、不良反应及疾病缓解情况。结果实验组患者随访1年的疾病无进展生存时间长于对照组,生存期间的生存质量评分高于对照组,差异有统计学意义(P<0.05);实验组的不良反应总发生率低于对照组,差异有统计学意义(P<0.05);实验组的疾病缓解率高于对照组,差异有统计学意义(P<0.05)。结论厄洛替尼治疗晚期非小细胞肺癌的临床效果显著,1年生存状况良好,不良反应发生率低,疾病缓解率高,推荐在临床治疗中优先选用此方案。

Objective To investigate the clinical effect of Erlotinib in the treatment of advanced non-small cell lung cancer.Methods A total of 176 patients with advanced non-small cell lung cancer admitted to the Zhongyi Northeast International Hospital from January 2017 to June 2019 were selected as the research objects.According to the random number table method,they were divided into the control group(88 cases)and the experimental group(88 cases).The control group was treated with Docetaxel,and the experimental group was treated with Erlotinib.The 1-year survival,adverse reactions and disease remission of the two groups were compared.Results During the follow-up period of 1 year,the disease progression free survival duration of the experimental group was longer than that of the control group,the quality of life score of the experimental group was higher than that of the control group,the differences were statistically significant(P<0.05);the total incidence rate of adverse reactions in the experimental group was lower than that in the control group,the difference was statistically significant(P<0.05);the disease remission rate of the experimental group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion Erlotinib has significant clinical effect in the treatment of advanced non-small cell lung cancer,with good 1-year survival,low incidence of adverse reactions and high disease remission rate.It is recommended that this option be preferred in clinical treatment.